We are live on ! Find out more
RGC icon

Regencell Bioscience
RGC

5 hedge funds and large institutions have $296K invested in Regencell Bioscience in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.09% less ownership

Funds ownership: 0.16% → 0.07% (-0.09%)

47% less capital inflows, than outflows

Capital inflows: $224K | Capital outflows: $419K

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$195K
2
UBS Group
UBS Group
Switzerland
+$13.7K
3
BlackRock
BlackRock
New York
+$6.82K
4
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$4.18K
5
Morgan Stanley
Morgan Stanley
New York
+$4.1K

Top Sellers

Rank Fund Capital Flow
1
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$371K
2
Citigroup
Citigroup
New York
-$48K

RGC Hedge Fund Activity: Q2 2022 in Review

5 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q2 2022, worth a combined $296K — down 32% from $434K a quarter earlier.

Fund positioning in RGC was balanced in Q2 2022: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $195K. The largest seller was Qube Research & Technologies (QRT), exiting entirely with an estimated $371K sold.

  • 5 institutional investors held Regencell Bioscience (RGC) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $296K of Regencell Bioscience stock for Q2 2022, down 32% quarter-over-quarter.
  • 2 funds opened new Regencell Bioscience positions in Q2 2022 and 2 closed out, a net change of 0 holders.
  • The largest Regencell Bioscience buyer in Q2 2022 was Geode Capital Management, an estimated $195K added.
  • The largest Regencell Bioscience seller in Q2 2022 was Qube Research & Technologies (QRT), an estimated $371K sold.

Based on aggregated 13F filings for Q2 2022.